Latest news

• Moderna seeks full FDA approval for its COVID-19 vaccine

  Moderna is seeking a full US Food and Drug Administration (FDA) approval for its COVID-19 vaccine mRNA-1273, after gaining an emergency use authorisation (EUA) for the jab late last ... year. Moderna’s mRNA-1273 vaccine became the second COVID-19

• Moderna’s COVID-19 vaccine offers high levels of protection for adolescents

  Using this definition, Moderna concluded that the vaccine efficacy for mRNA-1273 is 93% after the first dose. ... We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents.

• Moderna’s booster vaccines increase neutralising antibodies against COVID-19 variants

  The variant-specific booster candidate – mRNA-1273.351 – encodes for the spike protein of the SARS-CoV-2 variant B.1.351. ... The strong and rapid boost in titres to levels above primary vaccination also clearly demonstrates the ability of mRNA-1273

• Moderna’s booster vaccine for South African variant demonstrates promising early results

  Moderna’s authorised vaccine against ancestral strain and mRNA-1273.351 in a single vaccine. ... In particular, the data confirms improved neutralising titers from the mRNA-1273.351 vaccine, with the multivalent vaccine providing the broadest level of

• Moderna launches COVID-19 vaccine booster study to address new variants

  The phase 2 trial amendment has enrolled 60 participants who have already received  Moderna’s original mRNA-1273 vaccine. ... The variant-specific booster candidate – mRNA-1273.351 – encodes for the spike protein of the SARS-CoV-2 variant B.1.351,